BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Keshteli AH, Madsen KL, Mandal R, Boeckxstaens GE, Bercik P, De Palma G, Reed DE, Wishart D, Vanner S, Dieleman LA. Comparison of the metabolomic profiles of irritable bowel syndrome patients with ulcerative colitis patients and healthy controls: new insights into pathophysiology and potential biomarkers. Aliment Pharmacol Ther 2019;49:723-32. [PMID: 30706502 DOI: 10.1111/apt.15141] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Xue G, Hua L, Zhou N, Li J. Characteristics of immune cell infiltration and associated diagnostic biomarkers in ulcerative colitis: results from bioinformatics analysis. Bioengineered 2021;12:252-65. [PMID: 33323040 DOI: 10.1080/21655979.2020.1863016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
2 Husain H, Waseem M, Ahmad R. Proteomic and molecular evidences of Il1rl2, Ric8a, Krt18 and Hsp90b1 modulation during experimental hepatic fibrosis and pomegranate supplementation. Int J Biol Macromol 2021;185:696-707. [PMID: 34174316 DOI: 10.1016/j.ijbiomac.2021.06.091] [Reference Citation Analysis]
3 Chen M, Ruan G, Chen L, Ying S, Li G, Xu F, Xiao Z, Tian Y, Lv L, Ping Y, Cheng Y, Wei Y. Neurotransmitter and Intestinal Interactions: Focus on the Microbiota-Gut-Brain Axis in Irritable Bowel Syndrome. Front Endocrinol 2022;13:817100. [DOI: 10.3389/fendo.2022.817100] [Reference Citation Analysis]
4 Gros M, Gros B, Mesonero JE, Latorre E. Neurotransmitter Dysfunction in Irritable Bowel Syndrome: Emerging Approaches for Management. J Clin Med 2021;10:3429. [PMID: 34362210 DOI: 10.3390/jcm10153429] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Zhang Y, Wu XX, Li S, Wu JF, Han S, Lin ZJ, Ding SZ, Gong WJ. Peroxiredoxin 1 as an inflammatory marker in diarrhea-predominant and postinfectious irritable bowel syndrome. Neurogastroenterol Motil 2020;32:e13741. [PMID: 31613423 DOI: 10.1111/nmo.13741] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
6 Bennet SM, Keshteli AH, Bercik P, Madsen KL, Reed D, Vanner SJ. Application of metabolomics to the study of irritable bowel syndrome. Neurogastroenterol Motil 2020;32:e13884. [PMID: 32426922 DOI: 10.1111/nmo.13884] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
7 Pradeep S, Mehanna R. Gastrointestinal disorders in hyperkinetic movement disorders and ataxia. Parkinsonism Relat Disord 2021;90:125-33. [PMID: 34544654 DOI: 10.1016/j.parkreldis.2021.09.005] [Reference Citation Analysis]
8 James SC, Fraser K, Young W, McNabb WC, Roy NC. Gut Microbial Metabolites and Biochemical Pathways Involved in Irritable Bowel Syndrome: Effects of Diet and Nutrition on the Microbiome. J Nutr 2020;150:1012-21. [PMID: 31891398 DOI: 10.1093/jn/nxz302] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
9 Liu S, Si C, Yu Y, Zhao G, Chen L, Zhao Y, Zhang Z, Li H, Chen Y, Min L, Zhang S, Zhu S. Multi-omics Analysis of Gut Microbiota and Metabolites in Rats With Irritable Bowel Syndrome. Front Cell Infect Microbiol 2019;9:178. [PMID: 31192167 DOI: 10.3389/fcimb.2019.00178] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
10 Wilder-smith CH, Drewes AM, Materna A, Olesen SS. Symptoms of mast cell activation syndrome in functional gastrointestinal disorders. Scandinavian Journal of Gastroenterology 2019;54:1322-5. [DOI: 10.1080/00365521.2019.1686059] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
11 Hu W, Xu D, Zhou Z, Zhu J, Wang D, Tang J. Alterations in the gut microbiota and metabolic profiles coincide with intestinal damage in mice with a bloodborne Candida albicans infection. Microb Pathog 2021;154:104826. [PMID: 33689815 DOI: 10.1016/j.micpath.2021.104826] [Reference Citation Analysis]
12 Hu W, Huang L, Zhou Z, Yin L, Tang J. Diallyl Disulfide (DADS) Ameliorates Intestinal Candida albicans Infection by Modulating the Gut microbiota and Metabolites and Providing Intestinal Protection in Mice. Front Cell Infect Microbiol 2021;11:743454. [PMID: 35071031 DOI: 10.3389/fcimb.2021.743454] [Reference Citation Analysis]
13 Xie D, Li F, Pang D, Zhao S, Zhang M, Ren Z, Geng C, Wang C, Wei N, Jiang P. Systematic Metabolic Profiling of Mice with Dextran Sulfate Sodium-Induced Colitis. J Inflamm Res 2021;14:2941-53. [PMID: 34239317 DOI: 10.2147/JIR.S313374] [Reference Citation Analysis]
14 Yamamoto M, Shanmuganathan M, Hart L, Pai N, Britz-McKibbin P. Urinary Metabolites Enable Differential Diagnosis and Therapeutic Monitoring of Pediatric Inflammatory Bowel Disease. Metabolites 2021;11:245. [PMID: 33921143 DOI: 10.3390/metabo11040245] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Prakash S, Prakash A. Dopa responsive irritable bowel syndrome: restless bowel syndrome or a gastrointestinal variant of restless legs syndrome? BMJ Case Rep 2021;14:e240686. [PMID: 33762285 DOI: 10.1136/bcr-2020-240686] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Keshteli AH, Madsen KL, Mandal R, Boeckxstaens GE, Bercik P, De Palma G, Reed DE, Wishart D, Vanner S, Dieleman LA. Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission - confounded by the gut microbiome? Authors' reply. Aliment Pharmacol Ther 2019;49:1088-9. [PMID: 30920043 DOI: 10.1111/apt.15200] [Reference Citation Analysis]
17 Leong RWL, Kaakoush NO, Yau YY, Wasinger VC. Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission-confounded by the gut microbiome? Aliment Pharmacol Ther 2019;49:1086-7. [PMID: 30920041 DOI: 10.1111/apt.15171] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
18 Vernia F, Valvano M, Fabiani S, Stefanelli G, Longo S, Viscido A, Latella G. Are Volatile Organic Compounds Accurate Markers in the Assessment of Colorectal Cancer and Inflammatory Bowel Diseases? A Review. Cancers (Basel) 2021;13:2361. [PMID: 34068419 DOI: 10.3390/cancers13102361] [Reference Citation Analysis]
19 Zhang Y, Zhang L, Li S, Wu XX, Bi YX, Hu X, Chen YQ, Yuan Y. Serum levels of high sensitive C-reactive protein and tumor necrosis factor-alpha in different subtypes of irritable bowel syndrome and their correlation. Shijie Huaren Xiaohua Zazhi 2020; 28(16): 782-788 [DOI: 10.11569/wcjd.v28.i16.782] [Reference Citation Analysis]
20 Aldars-García L, Gisbert JP, Chaparro M. Metabolomics Insights into Inflammatory Bowel Disease: A Comprehensive Review. Pharmaceuticals (Basel) 2021;14:1190. [PMID: 34832973 DOI: 10.3390/ph14111190] [Reference Citation Analysis]
21 Xiao L, Liu Q, Luo M, Xiong L. Gut Microbiota-Derived Metabolites in Irritable Bowel Syndrome. Front Cell Infect Microbiol 2021;11:729346. [PMID: 34631603 DOI: 10.3389/fcimb.2021.729346] [Reference Citation Analysis]
22 Lu J, Wang Z, Maimaiti M, Hui W, Abudourexiti A, Gao F. Identification of diagnostic signatures in ulcerative colitis patients via bioinformatic analysis integrated with machine learning. Hum Cell 2021. [PMID: 34731452 DOI: 10.1007/s13577-021-00641-w] [Reference Citation Analysis]